SALT
LAKE CITY, July 21, 2022 /PRNewswire/ -- Recursion
(NASDAQ: RXRX), the clinical-stage biotechnology company
industrializing drug discovery by decoding biology, today announced
that the European Commission has granted Recursion Orphan Drug
Designation for REC-4881 for the potential treatment of familial
adenomatous polyposis (FAP). REC-4881 is an orally bioavailable,
non-ATP-competitive allosteric small molecule inhibitor of MEK1 and
MEK2 being developed to reduce polyp burden and progression to
adenocarcinoma in FAP patients.
Recursion discovered REC-4881 as a potential candidate for
treatment of FAP by leveraging its proprietary AI-powered drug
discovery platform, the Recursion OS.
"FAP is a rare tumor syndrome that affects approximately 50,000
patients in the US, France,
Germany, Italy, Spain
and the UK, with no approved therapies", said Meredith Brown-Tuttle, Vice President of
Regulatory Affairs. "Recursion is excited about this Orphan Drug
Designation in the European Union as we continue to advance towards
initiating a Phase 2 clinical trial."
Within the past 10 months, the U.S. Food and Drug Administration
(FDA) granted the company Orphan Drug and Fast Track
designations for REC-4881 to support the development and
evaluation of new treatments for FAP.
Learn more about Recursion at https://www.recursion.com/.
About REC-4881
REC-4881 is an orally bioavailable, non-ATP-competitive
allosteric small molecule inhibitor of MEK1 and MEK2 being
developed to reduce polyp burden and progression to adenocarcinoma
in FAP patients. REC-4881 has been well tolerated in prior clinical
studies, consistent with the intended use, and has a gut-localized
PK profile that may be advantageous for FAP, and potentially other
APC-driven gastrointestinal tumors. We expect to initiate a Phase
2, double-blind, randomized, placebo-controlled clinical trial of
REC-4881 in FAP by the end of this quarter.
About Familial Adenomatous
Polyposis
FAP is a rare tumor syndrome with no approved therapies. In the
US, France, Germany, Italy, Spain
and the UK alone the disease affects approximately 50,000 patients.
FAP is caused by autosomal dominant inactivating mutations in the
tumor suppressor gene APC. FAP patients develop polyps in the
gastrointestinal tract throughout their lives. These growths have a
high risk of malignant transformation and can give rise to invasive
cancers of the colon, stomach, duodenum, rectum, and other tissues.
Standard of care for patients with FAP is colectomy, and without
surgical intervention, affected patients will progress to
colorectal cancer in adulthood. Even after colectomy, patients
receive endoscopic surveillance every 6-12 months to monitor
disease progression. While surgical management and surveillance
have improved the prognosis for FAP patients, duodenal and desmoid
tumors remain major causes of death following colectomy in patients
with FAP.
About Recursion
Recursion is the clinical-stage biotechnology company
industrializing drug discovery by decoding biology. Enabling its
mission is the Recursion Operating System, a platform built across
diverse technologies that continuously expands one of the world's
largest proprietary biological and chemical datasets, the Recursion
Data Universe. Recursion leverages sophisticated machine-learning
algorithms to distill from its dataset the Recursion Map, a
collection of hundreds of billions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating one of the most powerful supercomputers in the world,
Recursion is uniting technology, biology and chemistry to advance
the future of medicine.
The Company is headquartered in Salt
Lake City, where it is a founding member of BioHive, the
Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at
www.Recursion.com, or connect on
Twitter and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking
Statements
This press release contains information that includes or is
based upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. Forward-looking
statements provide our expectations or forecasts regarding future
events. You can identify these statements by the fact they do not
relate strictly to historical or current facts. They may use words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other terms of similar meaning in connection
with a discussion of future operating or financial performance. In
particular, forward-looking statements include statements relating
to intended future actions; plans with respect to clinical trials
and preclinical activities; prospective products or product
approvals; future performance or results of anticipated products or
technology; expenses; our ability to obtain, maintain and enforce
intellectual property protections; and financial results, in
addition to other topics. Any or all of our forward-looking
statements here and elsewhere may turn out to be wrong. They can be
affected by inaccurate assumptions or by known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements and from
expected or historical results. Many such factors will be important
in determining our actual future results. Consequently, no
forward-looking statement can be guaranteed. In particular, you
should read the discussion in the "Risk Factors" section in our
Prospectus filed with the U.S. Securities and Exchange Commission
(SEC) on April 16, 2021 as well as in
our Form 10-K filed with the SEC on March
23, 2022 and our other periodic filings with the SEC. Other
factors besides those listed could also adversely affect the
company. We undertake no obligation to correct or update any
forward-looking statements, whether as a result of new information,
future developments or otherwise, except to the extent required by
applicable law. These forward-looking statements (except as may be
otherwise noted) speak only as of the date of this press release.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. You are advised to consult any further disclosures we
make on related subjects in our reports to the SEC.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recursion-is-granted-eu-orphan-drug-designation-for-rec-4881-for-the-potential-treatment-of-familial-adenomatous-polyposis-301590655.html
SOURCE Recursion